The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors-Reference-Cited by-同舟云学术

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors

Published:2021-02 Issue:1 Volume:6 Page:100008
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Araujo-Fernandez I.,Delgado J.,Moscetti L.,Sarac S.B.,Zander H.,Mueller-Egert S.,Dunder K.,Pean E.,Bergmann L.,Enzmann H.,Pignatti F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Cancer immunoediting: from immunosurveillance to tumor escape;Dunn;Nat Immunol,2002

2. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

5. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of the immune environment in pregnancy-associated breast cancer;Future Oncology;2023-05

2. Computational pathology to improve biomarker testing in breast cancer: how close are we?;European Journal of Cancer Prevention;2023-04-10

3. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis;Cancer Treatment Reviews;2022-03

4. Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures;International Journal of Molecular Sciences;2022-02-18

5. Microenvironmental regulation of tumour immunity and response to immunotherapy;The Journal of Pathology;2021-05-19